Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02675231 · ClinicalTrials.gov registry record · Phase 2
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 237
- Enrollment target
NCT02675231 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 237 participants.
The verdict
NCT02675231, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 237 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus physicians choice standard of care chemotherapy in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 positive (HER2+) locally advanced or metastatic breast cancer after prior exposure to at least two HER2-directed therapies for advanced disease.
Interventions
- DRUG Trastuzumab
- DRUG Fulvestrant
- DRUG Abemaciclib
- DRUG Standard of Care Single Agent Chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2016-05-23 |
| Est. Completion | 2023-11-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02675231
The ClinicalTrials.gov registry entry for NCT02675231 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 237 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Trastuzumab is the first listed.
NCT02675231 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02675231 about?
NCT02675231 is a clinical study titled "A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer". The purpose of this study is to evaluate the effectiveness of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus physicians choice standard of care chemotherapy in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 positive (HER2+) loca...
What is the current status of trial NCT02675231?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 237 participants. The study started on 2016-05-23. Estimated completion is 2023-11-09.
What interventions are being tested in trial NCT02675231?
The interventions under investigation include: Trastuzumab (DRUG), Fulvestrant (DRUG), Abemaciclib (DRUG), Standard of Care Single Agent Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT02675231?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.